Company Description
LB Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases.
We are building a pipeline that leverages the broad therapeutic potential of our lead product candidate, LB-102, which we believe has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States.
LB-102 is a new chemical entity and a methylated derivative of amisulpride, a second-generation antipsychotic drug approved in over 50 countries that has been extensively used in clinical practice following its initial approval in France in the 1980s.
We believe LB-102’s mechanism of action, data from our recently completed Phase 2 trial of LB-102 in acute schizophrenia, and the legacy of clinical experience with amisulpride support the continued development of LB-102 in schizophrenia and bipolar depression.
| Country | United States |
| Founded | 2015 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 16 |
| CEO | Heather Turner |
Contact Details
Address: One Pennsylvania Plaza, Suite 1025 New York, NY 10119 United States | |
| Phone | (212) 605-0300 |
| Website | lbpharma.us |
Stock Details
| Ticker Symbol | LBRX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001691082 |
| SIC Code | 2834 |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 22, 2025 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Jul 23, 2025 | DRS/A | [Amend] [Cover] Draft Registration Statement |
| Jun 24, 2024 | DRS/A | [Amend] [Cover] Draft Registration Statement |
| May 20, 2024 | DRS | [Cover] Draft Registration Statement |
| Jan 10, 2024 | D/A | Filing |
| Sep 21, 2023 | D | Notice of Exempt Offering of Securities |
| Nov 23, 2022 | D/A | Filing |
| Nov 1, 2022 | D | Notice of Exempt Offering of Securities |
| Jul 6, 2022 | D | Notice of Exempt Offering of Securities |
| Sep 1, 2020 | D | Notice of Exempt Offering of Securities |